Fraser S M, Sturrock R D
Centre for Rheumatic Diseases, University Department of Medicine, Royal Infirmary, Glasgow.
Br J Rheumatol. 1990 Feb;29(1):37-9. doi: 10.1093/rheumatology/29.1.37.
Sulphasalazine has recently been shown to have an effect in ankylosing spondylitis but the clinical indication for its use is controversial. We have used an 'interventional' study design to investigate the clinical and laboratory effects of sulphasalazine in a group of 20 patients with active ankylosing spondylitis and peripheral joint disease. Following an initial assessment period, patients were treated with sulphasalazine for 24 weeks and the drug was then withdrawn and the patients monitored for a further 12 weeks. Significant improvements were observed in chest expansion, number of active joints, ESR and CRP which deteriorated after withdrawal of sulphasalazine. No change in spinal mobility was demonstrated. The 'interventional' design may be a useful screening procedure for identifying potential second line drugs in ankylosing spondylitis.
柳氮磺胺吡啶最近已被证明对强直性脊柱炎有疗效，但其临床应用指征仍存在争议。我们采用了“干预性”研究设计，以调查柳氮磺胺吡啶对一组20例患有活动性强直性脊柱炎和外周关节疾病患者的临床及实验室影响。在初始评估期之后，患者接受柳氮磺胺吡啶治疗24周，然后停药，并对患者进一步监测12周。观察到在停药后恶化的胸廓扩张度、活动关节数量、血沉和C反应蛋白均有显著改善。未显示脊柱活动度有变化。“干预性”设计可能是一种有用的筛选程序，用于识别强直性脊柱炎潜在的二线药物。
